Medivation Battles UCLA Over Rights To Prostate Cancer Compound
UCLA researchers secretly developed a compound almost identical to Medivation’s MDV3100 (enzalutamide), a breach of contract suit claims. The company expects to launch MDV3100 later this year.
You may also be interested in...
The San Diego biotech’s Series D round will support continued development of a drug that Medivation claims was included in the same license that covered the recently approved prostate cancer drug Xtandi.
Medivation and Astellas have submitted their castration-resistant prostate cancer drug enzalutamide to FDA and hope to gain priority review for the long-anticipated therapy.
A second failed efficacy trial, CONCERT, provided the final nail in the coffin for the once-promising treatment for Alzheimer’s disease, serving as a cautionary tale against excessive enthusiasm for early clinical trial results.